Aignostics

Aignostics is a Berlin-based, Charité spin-off founded in 2018, operating at the intersection of AI, digital pathology, and oncology. The company has developed a robust platform centered on proprietary pathology foundation models, which power its products (like the Atlas H&E-TME application) and custom services for biopharma partners. With access to multimodal data from over 30 million patients, deep collaborations with academic institutions like Mayo Clinic, and key industry partnerships (e.g., Bayer), Aignostics is positioned as a leading AI enabler for precision medicine in pathology and drug development. It is a private, likely revenue-generating company providing a mix of platform technology and bespoke analytical services.

Proprietary AI platform centered on pathology foundation models (e.g., Atlas 2 co-developed with Mayo Clinic) for analyzing digital pathology images. The platform enables tasks like tumor microenvironment profiling, cell classification, and multimodal data integration, with a focus on explainable AI (xAI) for target and biomarker discovery.

Aignostics competes in the growing digital pathology AI market against other AI-native startups (e.g., PathAI, Paige, Owkin), established diagnostic companies developing AI tools, and large tech firms (e.g., Google Health). Its differentiation lies in its proprietary foundation models co-developed with Mayo Clinic, deep biomedical expertise, explicit focus on the biopharma drug development pipeline, and strong academic/industry partnerships.